Atrasentan Market

Atrasentan Market is experiencing a CAGR of 6.2% during the forecast period from 2025-2035. This growth is primarily driven by the increasing prevalence of chronic kidney diseases (CKD) and diabetic nephropathy, rising R&D investments in nephrology therapeutics, and advancements in selective endothelin receptor antagonist development. Atrasentan, a highly selective ETA receptor antagonist, has shown promising results in reducing proteinuria and slowing kidney function decline, making it a strong candidate for use in late-stage clinical and commercial applications.

The key market segment driving demand is diabetic nephropathy and IgA nephropathy under the chronic kidney disease (CKD) application area, owing to the rising global burden of diabetes and kidney-related complications. Pharmaceutical companies are prioritizing atrasentan-based therapies as targeted treatments for proteinuric kidney diseases due to its mechanism of action and clinical efficacy. This has created strong interest in commercial-scale API manufacturing and CDMO partnerships.

North America is the leading regional market, accounting for the highest share due to advanced healthcare infrastructure, a robust clinical pipeline, and the presence of key industry players such as Novartis AG, which acquired Chinook Therapeutics, the innovator behind atrasentan’s current development for IgA nephropathy. The US Additionally benefits from regulatory incentives for orphan and breakthrough therapies in nephrology.

As atrasentan approaches regulatory approval, demand for high-quality API is expected to increase significantly, particularly from CDMOs and pharmaceutical companies engaged in late-stage formulation and commercialization. The market may expand further following patent expiry, potentially allowing generic API manufacturers in India and China to enter and drive competitive pricing.

Overall, the Atrasentan Market reflects a high-value niche opportunity in the broader nephrology pharmaceutical landscape.

Recent Development

• In April 2025, Novartis received accelerated approval from the FDA for Vanrafia (atrasentan), a potent endothelin A receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. The treatment is a once-daily, non-steroidal, oral treatment that can be added to supportive care, including a renin-angiotensin system inhibitor.